Navigation Links
Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
Date:5/17/2011

sly used other oral ED therapies. Each of these trials has a similar trial design with patients undergoing a four-week, non-treatment run-in period followed by 12 weeks of treatment. Primary endpoints of the studies are improvement in erectile function as measured by the Sexual Encounter Profile (SEP) and improvements in the EF domain score of the International Index of Erectile Function (IIEF). In both the TA-301 and TA-302 studies, all doses of avanafil met the primary endpoints, with successful intercourse achieved by some subjects in 15 minutes or less after administration. TA-314 was an open label, long-term safety and efficacy study required as part of the NDA.  In TA-314, patients also had significant improvement in erectile function as measured by SEP2, SEP3 and IIEF. 

VIVUS has also held a pre-NDA meeting with the FDA to confirm that the pre-clinical and clinical requirements necessary for the filing of an NDA have been met. In total, the phase 3 avanafil clinical program enrolled approximately 1,350 subjects. VIVUS expects to file the NDA for avanafil in the second quarter of 2011.

About Erectile Dysfunction (ED)Erectile Dysfunction (ED) is defined as the inability to attain and maintain an erection sufficient for sexual intercourse. According to the Massachusetts Male Aging Study (MMAS), ED affects an estimated 52 percent of men between the ages of 40 and 70. The prevalence of ED increases with age and can be affected by a variety of factors, including certain medications such as anti-hypertensives and histamine receptor antagonists; lifestyle, such as tobacco or alcohol use; diseases, including diabetes and cardiovascular conditions; and spinal cord injuries. Studies have shown that up to 58% of men with diabetes have erectile dysfunction.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigat
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... 2014 Reportbuyer.com has added a new ... Lasers and Energy Devices Market Outlook to 2020, ... Brazil Aesthetic Lasers and Energy Devices Market ... GlobalData,s new report, "Brazil Aesthetic Lasers and ... market data on the Brazil Aesthetic Lasers and ...
(Date:9/1/2014)... NEW YORK , Sept. 1, 2014 /PRNewswire/ ... new market research report is available in its ... Edition), 2014 - 2024 ... conjugates (ADCs) are a new class of therapeutic ... small pharmaceutical companies. Generally addressed as the marriage ...
(Date:9/1/2014)... 1, 2014 Reportlinker.com announces that a ... catalogue:  Drug Discovery Technologies - A Global ... The development of new drugs ... extensive expenditure, in addition to consuming a lot ... new drug involves the utilizing high-throughput screening of ...
Breaking Medicine Technology:Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18Drug Discovery Technologies - A Global Market Overview 2Drug Discovery Technologies - A Global Market Overview 3Drug Discovery Technologies - A Global Market Overview 4Drug Discovery Technologies - A Global Market Overview 5Drug Discovery Technologies - A Global Market Overview 6Drug Discovery Technologies - A Global Market Overview 7Drug Discovery Technologies - A Global Market Overview 8Drug Discovery Technologies - A Global Market Overview 9Drug Discovery Technologies - A Global Market Overview 10Drug Discovery Technologies - A Global Market Overview 11
... Israel--(BUSINESS WIRE)--Jun 14, 2007 - Can-Fite,BioPharma (TASE:CFBI), a ... Exchange, proceeds with the development of its,third drug ... is currently,in clinical trials and CF102, which is ... the EUALR annual congress of,rheumatology in-vitro and in ...
... of SLE,disease at 52 Weeks and demonstrated ... ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ -- ... of Phase 2,trial data demonstrating that LymphoStat-B(R) ... was well tolerated and improved quality of ...
Cached Medicine Technology:Can-Fite Proceeds with Development of Third Drug; Progress in,Development of CF502 Will Be Presented at the Annual European,Congress of Rheumatology 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 7Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 8
(Date:9/1/2014)... Windows web hosting provides a Windows based server ... recent years, and the new demand has resulted in ... that offer a variety of different services at very ... professional Windows web hosting suppliers from the USA and ... suppliers for webmasters who want to buy high quality ...
(Date:9/1/2014)... Citrus Park Endodontics , a dental specialty ... Tampa, Florida, announced the launch of its new website ... making the patient experience at Citrus Park Endodontics better. ... that truly make the website aesthetically pleasing. , “Our ... pleasant as our office experience is for our patients,” ...
(Date:9/1/2014)... Securityhunter has experienced rapid growth over the ... a new, larger headquarters. The newly renovated headquarters ... of our office to 10,000 square feet. We are ... topped cubicles with doors, to beautiful large conference rooms, to ... Michael S. Rogers, CEO of Securityhunter. “Our new facility ...
(Date:9/1/2014)... NAPW honors Victoria ... a 2014 Professional Woman of the Year. Ms. Smith ... office management. As the largest, most-recognized networking organization of ... and profession, the National Association of Professional Women is ... and nearly 300 Local Chapters. , Managing a busy ...
(Date:9/1/2014)... NAPW honors Bonnie E. ... Professional Woman of the Year for leadership in marketing ... the largest networking organization of women in the country, ... powerfully vibrant networking community with over 600,000 members and ... Ms. Vermillion enjoyed a successful career in materials management ...
Breaking Medicine News(10 mins):Health News:SEO Hosting Review Site Top10BestSEOHosting.com: Best Windows Web Hosting Suppliers From the USA Now Unveiled 2Health News:Citrus Park Endodontics Launches New Website to Better Serve Patients 2Health News:Securityhunter, Inc. Announces the Relocation of Its Corporate Headquarters in Baltimore 2Health News:National Association of Professional Women Announces Victoria Smith, Office Manager at Apex Healthcare, LLC, a 2014 Professional Woman of the Year 2Health News:National Association of Professional Women Announces Bonnie E. Vermillion, Owner at BEV, LLC, a 2014 Professional Woman of the Year 2
... DARIEN, Ill., June 17 Healthation CEO Scott ... Vice President of,Business Development today. Mr. Hebert was ... experience in sales of complex solutions in the ... the sales and,marketing organization and growing market share ...
... PartsSource, the nation,s leading,supplier of replacement medical ... straight "World Class Customer Service" award for Northern,Ohio. ... Promise and,its ability to consistently meet or exceed ... by Smart Business magazine, which further,honored PartsSource,s President ...
... NORTH HOLLYWOOD, Calif., June 17 IPC The,Hospitalist ... national hospitalist,physician group practice, today announced that it ... and Exchange Commission in connection,with a proposed offering ... shares to be registered include 3,889,769 shares owned ...
... extract reduces plaque formation and resulting cognitive impairment in ... The study appears in the June 18 issue of ... study author Giulio Pasinetti, MD, PhD, of Mount Sinai ... seed extract prevents amyloid beta accumulation in cells, suggesting ...
... researchers at Washington University School of Medicine in St. ... the risk of metabolic syndrome, a group of factors ... found appeared to protect against the condition. , People ... following symptoms: abdominal obesity, high blood triglyceride levels, lower ...
... and stress-reduction spur healthy alterations in DNA, study finds, ... not fully control your destiny when it comes to ... with prostate cancer. , New research suggests that stringent ... can change the expression of hundreds of genes. ...
Cached Medicine News:Health News:IPC The Hospitalist Company, Inc. Files Registration Statement for Proposed Offering 2Health News:IPC The Hospitalist Company, Inc. Files Registration Statement for Proposed Offering 3Health News:Study indicates grape seed extract may reduce cognitive decline associated with Alzheimer's disease 2Health News:Study indicates grape seed extract may reduce cognitive decline associated with Alzheimer's disease 3Health News:Gene variants linked to metabolic syndrome and HDL cholesterol levels 2Health News:Gene variants linked to metabolic syndrome and HDL cholesterol levels 3Health News:Lifestyle Changes Affect Cancer Genes 2Health News:Lifestyle Changes Affect Cancer Genes 3